Expert Review of Vaccines
Volume 21, 2022 - Issue 2
Open access
8,645
Views
6
CrossRef citations to date
0
Altmetric
Review
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy
Guilhem Richarda EpiVax Therapeutics, Inc., Providence, RI, USACorrespondence[email protected]
https://orcid.org/0000-0002-6544-4257
Michael F. Princiottaa EpiVax Therapeutics, Inc., Providence, RI, USA
https://orcid.org/0000-0002-8234-6771
Dominique Bridona EpiVax Therapeutics, Inc., Providence, RI, USA
, William D. Martinb EpiVax, Inc., Providence, RI, USA
https://orcid.org/0000-0001-8694-494X
Gary D. Steinberga EpiVax Therapeutics, Inc., Providence, RI, USA;c Perlmutter Cancer Center, Department of Urology at NYU Grossman School of Medicine, NYU Langone Health, New York, NY, USA
https://orcid.org/0000-0003-4469-0624
Anne S. De Grootb EpiVax, Inc., Providence, RI, USA;d Center for Vaccines and Immunology, University of Georgia, Athens, GA, USA
https://orcid.org/0000-0001-5911-1459
Pages 173-184
|
Received 27 Aug 2021, Accepted 26 Nov 2021, Published online: 19 Dec 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.